Evicenter
P&T meetings

Lytenava (bevacizumab-vikg)

Neovascular age-related macular degeneration

Regulatory submission
BLA approved July 2026
Last updated
50 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Anti-VEGF biosimilars

3 evidence topics · 2 sources

Ranibizumab biosimilars

“ranibizumab-nuna (Byooviz; Biogen/Samsung Bioepis), was approved in September 2021 for wet AMD, RVO, and myopic CNV.” (opens the source at this quote in a new tab)

“ranizumab-eqrn (Cimerli; Coherus Biosciences), was FDA approved in both 0.3 mg and 0.5 mg doses in October 2022 for DME, diabetic retinopathy (DR), wet AMD, RVO, and myopic CNV.” (opens the source at this quote in a new tab)

“first FDA-designated interchangeable biosimilar, meaning it can be substituted for reference ranibizumab at the pharmacy level” (opens the source at this quote in a new tab)

Anticipated cost savings from biosimilars

“biosimilars are estimated to cost patients around 30% to 40% less than the original biologic.” (opens the source at this quote in a new tab)

Agents included in current comparative evidence

“aflibercept 2 mg, aflibercept 8 mg, bevacizumab 1.25 mg (off‐label or on‐label), brolucizumab 6 mg, faricimab 6 mg, ranibizumab 0.5 mg, and the corresponding biosimilars.” (opens the source at this quote in a new tab)